Brief: Terns Pharmaceuticals Q3 Net Income USD -24.635 Million Vs. IBES Estimate USD -27.2 Million
Nov 10 (Reuters) - Terns Pharmaceuticals Q3 pretax profit USD -24.589 million vs. IBES estimate USD -27.2 million. Q3 operating expenses USD 27.716 million Q3 income from operations USD -27.716 million vs. IBES estimate USD -29.5 million Q3 basic EPS USD -0.27
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.